

Amendments

In the claims:

1. (withdrawn) A bifunctional protein comprising:
 - 1) an antigen binding domain derivable from a monoclonal antibody directed against a suitable antigen on a tumor cell;
 - 2) a hinge region comprising from about 40 to about 200 amino acids, and
 - 3) a functional zeta (ζ) chain derivable from the T-cell antigen receptor (TCR).
2. (currently amended) A DNA encoding a bifunctional protein, wherein said protein comprises SEQ ID NO:7 [
 - (i) an antigen binding domain derivable from an anti-ErbB2 antibody;
 - (ii) a hinge region comprising from about 40 to about 200 amino acids, and
 - (iii) a functional zeta (ζ) chain derivable from the T-cell antigen receptor (TCR); wherein the hinge region couples the antigen binding domain to the functional zeta chain].
3. (canceled) A DNA according to claim 2 encoding a protein wherein the antigen binding domain is a sequence produced by a hybridoma cell line having a deposit number selected from the group consisting of 90112115, 90112116, 90112117, and 90112118.

4. (canceled) A DNA according to claim 2 encoding a protein wherein the hinge region is from an immunoglobulin-like protein.
5. (canceled) A DNA according to claim 2 encoding a protein wherein the functional zeta (ζ) chain comprises the transmembrane and the cytoplasmic domain of the zeta chain.
6. (currently amended) **[A] An in vitro or ex vivo** host cell expressing the DNA claim 2.
7. (previously presented) A host cell according to claim 6 which is a cytotoxic lymphocyte (CTL).
8. (withdrawn) . A process for lysing selected tumor cells comprising contacting said tumor cells with CTL producing the protein of claim 1.
9. (currently amended) **[A] An in vitro or ex vivo** process for endowing a CTL with a defined, MHC-independent and MHC-unrestricted tumor cell specificity comprising introducing into said CTL the DNA of claim 2.
10. (currently amended) A method for the **[production] expression** of a bifunctional protein comprising: culturing a host cell containing DNA encoding said protein under conditions which allow the expression of a protein encoded by the DNA of claim 2[; **and removing bifunctional protein from the host cell culture**].
11. (previously presented) A composition-of-matter comprising a host cell according to claim 7.

12. (withdrawn) A method of treating cancer comprising the use of a host cell according to claim 7.

13. (previously presented) A method of treating cancer, comprising contacting the cancer with CTL that expresses the DNA described in claim 2.

14. (withdrawn) Polyclonal or monoclonal antibody specific for a protein according to claim 1.

15. (currently amended) A [V]vector comprising a DNA according to claim 2.

16. (New) The DNA of claim 2, wherein said protein comprises the amino acid sequence as shown in SEQ ID NO:6.

17. (New) The DNA of claim 16, comprising the nucleotide sequence as shown in SEQ ID NO:5.